Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.

Document Type

Article

Publication Date

1-1-2023

Publication Title

NEJM evidence

Abstract

BACKGROUND: Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR)

METHODS: The OVERCOME (Colistin Monotherapy versus Combination Therapy) trial was an international, randomized, double-blind, placebo-controlled trial. We randomly assigned participants to receive colistin (5 mg/kg once followed by 1.67 mg/kg every 8 hours) in combination with either meropenem (1000 mg every 8 hours) or matching placebo for the treatment of pneumonia and/or BSI caused by XDR A.

RESULTS: Between 2012 and 2020, a total of 464 participants were randomly assigned to treatment, and 423 eligible patients comprised the modified intention-to-treat population.

CONCLUSIONS: Combination therapy with colistin and meropenem was not superior to colistin monotherapy for the treatment of pneumonia or BSI caused by these pathogens. (Funded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases protocol 10-0065; ClinicalTrials.gov number, NCT01597973.).

Volume

2

Issue

1

DOI

10.1056/evidoa2200131

ISSN

2766-5526

PubMed ID

37538951

Link to Full Text

Share

COinS